메뉴 건너뛰기




Volumn 23, Issue 3, 2011, Pages 290-296

Novel agents and new therapeutics in castration-resistant prostate cancer

Author keywords

abiraterone acetate; cabazitaxel; castration resistant prostate cancer; immunotherapy; intermittent androgen deprivation therapy; MDV3100

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENOSUMAB; DOCETAXEL; IPILIMUMAB; KETOCONAZOLE; MDX 1106; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC; PROVENGE; STEROID; TAK 700; TOK 001; UNCLASSIFIED DRUG; XL 184; ZOLEDRONIC ACID;

EID: 79954994034     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283449400     Document Type: Review
Times cited : (27)

References (45)
  • 1
    • 67650410937 scopus 로고    scopus 로고
    • American Cancer Society Atlanta, GA: American Cancer Society
    • American Cancer Society. Cancer facts & figures 2009. Atlanta, GA: American Cancer Society, 2009.
    • (2009) Cancer Facts & Figures 2009
  • 2
    • 33751581744 scopus 로고    scopus 로고
    • Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy
    • DOI 10.1016/j.clinthera.2006.10.018, PII S014929180600258X
    • Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of PCa: a review of their discovery, development, and place in therapy. Clin Ther 2006; 28:1485-1508. (Pubitemid 44841984)
    • (2006) Clinical Therapeutics , vol.28 , Issue.10 , pp. 1485-1508
    • Moreau, J.-P.1    Delavault, P.2    Blumberg, J.3
  • 3
    • 65049090443 scopus 로고    scopus 로고
    • Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomized phase 3 study of the South European Uroncological Group
    • Calais da Silva FEC, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55:1269-1277.
    • (2009) Eur Urol , vol.55 , pp. 1269-1277
    • Calais Da Silva, F.E.C.1    Bono, A.V.2    Whelan, P.3
  • 4
    • 0037009822 scopus 로고    scopus 로고
    • A randomised, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma
    • Saad F, Gleason DM, Murray R, et al. A randomised, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1458-1468
    • Saad, F.1    Gleason, D.M.2    Murray, R.3
  • 5
    • 69049105440 scopus 로고    scopus 로고
    • Denosumab in men receiving androgen-deprivation therapy for prostate cancer
    • Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
    • (2009) N Engl J Med , vol.361 , pp. 745-755
    • Smith, M.R.1    Egerdie, B.2    Hernandez Toriz, N.3
  • 6
    • 78349290889 scopus 로고    scopus 로고
    • A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer
    • suppl; abstr LBA4507
    • Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2010; 28:18s (suppl; abstr LBA4507).
    • (2010) J Clin Oncol , vol.28
    • Fizazi, K.1    Carducci, M.A.2    Smith, M.R.3
  • 7
    • 34648828214 scopus 로고    scopus 로고
    • Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
    • DOI 10.1002/cncr.22933
    • Saigal CS, Gore JL, KrupskiTL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110:1493-1500. (Pubitemid 47463063)
    • (2007) Cancer , vol.110 , Issue.7 , pp. 1493-1500
    • Saigal, C.S.1    Gore, J.L.2    Krupski, T.L.3    Hanley, J.4    Schonlau, M.5    Litwin, M.S.6
  • 8
    • 78650972549 scopus 로고    scopus 로고
    • Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation
    • Nguyen PL, Chen MH, Goldhaber SZ, et al. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer 2011; 117:406-413.
    • (2011) Cancer , vol.117 , pp. 406-413
    • Nguyen, P.L.1    Chen, M.H.2    Goldhaber, S.Z.3
  • 9
    • 66649136169 scopus 로고    scopus 로고
    • Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer
    • Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115:2388-2399.
    • (2009) Cancer , vol.115 , pp. 2388-2399
    • Taylor, L.G.1    Canfield, S.E.2    Du, X.L.3
  • 10
    • 58149337570 scopus 로고    scopus 로고
    • Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31
    • Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27:92-99.
    • (2009) J Clin Oncol , vol.27 , pp. 92-99
    • Efstathiou, J.A.1    Bae, K.2    Shipley, W.U.3
  • 11
    • 70249149328 scopus 로고    scopus 로고
    • Impact of androgen deprivation therapy on cardiovascular disease and diabetes
    • Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27:3452-3458.
    • (2009) J Clin Oncol , vol.27 , pp. 3452-3458
    • Alibhai, S.M.1    Duong-Hua, M.2    Sutradhar, R.3
  • 12
    • 51049098138 scopus 로고    scopus 로고
    • Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
    • Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68:6407-6415.
    • (2008) Cancer Res , vol.68 , pp. 6407-6415
    • Locke, J.A.1    Guns, E.S.2    Lubik, A.A.3
  • 13
    • 49249119358 scopus 로고    scopus 로고
    • Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
    • Montgomery RB, Mostaghel EA, Vessel la R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68:4447-4454.
    • (2008) Cancer Res , vol.68 , pp. 4447-4454
    • Montgomery, R.B.1    Mostaghel, E.A.2    Vessel La, R.3
  • 15
    • 70350244512 scopus 로고    scopus 로고
    • Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens
    • Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69:8141-8149.
    • (2009) Cancer Res , vol.69 , pp. 8141-8149
    • Waltering, K.K.1    Helenius, M.A.2    Sahu, B.3
  • 16
    • 77951786995 scopus 로고    scopus 로고
    • Prolonged treatment with bicalu- tamide induces androgen receptor overexpression and androgen hypersen sitivity
    • Kawata H, Ishikura N, Watanabe M, et al. Prolonged treatment with bicalu- tamide induces androgen receptor overexpression and androgen hypersen sitivity. Prostate 2010; 70:745-754.
    • (2010) Prostate , vol.70 , pp. 745-754
    • Kawata, H.1    Ishikura, N.2    Watanabe, M.3
  • 17
    • 77955296562 scopus 로고    scopus 로고
    • Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
    • Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120:271 5-2730.
    • (2010) J Clin Invest , vol.120 , pp. 2715-2730
    • Sun, S.1    Sprenger, C.C.2    Vessella, R.L.3
  • 18
    • 50249125379 scopus 로고    scopus 로고
    • Androgen regulation of the androgen receptor coregulators
    • Urbanucci A, Waltering KK, Suikki HE, et al. Androgen regulation of the androgen receptor coregulators. BMC Cancer 2008; 8:219-228.
    • (2008) BMC Cancer , vol.8 , pp. 219-228
    • Urbanucci, A.1    Waltering, K.K.2    Suikki, H.E.3
  • 19
    • 65649090203 scopus 로고    scopus 로고
    • Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    • Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-790.
    • (2009) Science , vol.324 , pp. 787-790
    • Tran, C.1    Ouk, S.2    Clegg, N.J.3
  • 20
    • 77952105685 scopus 로고    scopus 로고
    • Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
    • Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446.
    • (2010) Lancet , vol.375 , pp. 1437-1446
    • Scher, H.I.1    Beer, T.M.2    Higano, C.S.3
  • 21
    • 53749090666 scopus 로고    scopus 로고
    • Phase i clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
    • Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-4571.
    • (2008) J Clin Oncol , vol.26 , pp. 4563-4571
    • Attard, G.1    Reid, A.H.2    Yap, T.A.3
  • 22
    • 68949094223 scopus 로고    scopus 로고
    • Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
    • Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-3748.
    • (2009) J Clin Oncol , vol.27 , pp. 3742-3748
    • Attard, G.1    Reid, A.H.2    A'Hern, R.3
  • 23
    • 77951523950 scopus 로고    scopus 로고
    • Phase i clinical trial of the CYP1 7 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration- resistant prostate cancer who received prior ketoconazole therapy
    • Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP1 7 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration- resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-1488.
    • (2010) J Clin Oncol , vol.28 , pp. 1481-1488
    • Ryan, C.J.1    Smith, M.R.2    Fong, L.3
  • 24
    • 70349740108 scopus 로고    scopus 로고
    • Phase II multicenter study of chemother apy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone
    • suppl; abstract 5046
    • Ryan C, Efstathiou E, Smith M, et al. Phase II multicenter study of chemother apy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 2009; 27(Suppl.): abstract 5046.
    • (2009) J Clin Oncol , vol.27
    • Ryan, C.1    Efstathiou, E.2    Smith, M.3
  • 25
    • 77951518711 scopus 로고    scopus 로고
    • Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
    • Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-1495.
    • (2010) J Clin Oncol , vol.28 , pp. 1489-1495
    • Reid, A.H.1    Attard, G.2    Danila, D.C.3
  • 26
    • 77951591066 scopus 로고    scopus 로고
    • Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel- treated castration-resistant prostate cancer
    • Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel- treated castration-resistant prostate cancer. J Clin Oncol 2010; 28:1496- 1501.
    • (2010) J Clin Oncol , vol.28 , pp. 1496-1501
    • Danila, D.C.1    Morris, M.J.2    De Bono, J.S.3
  • 27
    • 79954995219 scopus 로고    scopus 로고
    • Use of 'intracrine androgen signaling signature' to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC)
    • suppl; abstract 4547
    • Efstathiou E, Tu S, Aparicio A. et al. Use of 'intracrine androgen signaling signature' to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 2010; 28(Suppl.): abstract 4547.
    • (2010) J Clin Oncol , vol.28
    • Efstathiou, E.1    Tu, S.2    Aparicio, A.3
  • 28
    • 78649919788 scopus 로고    scopus 로고
    • Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: Results of COU-AA-201, a randomized double-blind placebo-controlled phase 3 study
    • Presented at the
    • de Bono JS, Logothetis C, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: results of COU-AA-201, a randomized double-blind placebo-controlled phase 3 study. Presented at the 2010 European Society for Medical Oncology (ESMO) Annual Meeting, 2010.
    • (2010) 2010 European Society for Medical Oncology (ESMO) Annual Meeting
    • De Bono, J.S.1    Logothetis, C.2    Fizazi, K.3
  • 29
    • 78649523986 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and efficacy of TAK-700 in castration- resistant, metastatic prostate cancer: A phase I/II, open-label study
    • suppl; abstract 103
    • Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study. J Clin Oncol 2010; 28:18s (Suppl.; abstract 103).
    • (2010) J Clin Oncol , vol.28
    • Dreicer, R.1    Agus, D.B.2    MacVicar, G.R.3
  • 33
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial
    • de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 1147-1154.
    • (2010) Lancet , vol.376 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 34
    • 77955714649 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo- controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration- resistant prostate cancer (mCRPC): Survival results of CALGB 90401
    • suppl; abstract LBA4511
    • Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo- controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration- resistant prostate cancer (mCRPC): Survival results of CALGB 90401 .J Clin Oncol 2010; 28:18s (Suppl.; abstract LBA4511).
    • (2010) J Clin Oncol , vol.28
    • Kelly, W.K.1    Halabi, S.2    Carducci, M.A.3
  • 35
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
    • (2010) N Engl J Med , vol.363 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 37
    • 68549135290 scopus 로고    scopus 로고
    • Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-Tin advanced prostate cancer
    • Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-Tin advanced prostate cancer. Cancer 2009; 115:3670-3679.
    • (2009) Cancer , vol.115 , pp. 3670-3679
    • Higano, C.S.1    Schellhammer, P.F.2    Small, E.J.3
  • 39
    • 77949895922 scopus 로고    scopus 로고
    • Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
    • Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-1105.
    • (2010) J Clin Oncol , vol.28 , pp. 1099-1105
    • Kantoff, P.W.1    Schuetz, T.J.2    Blumenstein, B.A.3
  • 40
    • 66249105438 scopus 로고    scopus 로고
    • Phase i trial of ipilimumab alone (or in combination with radiotherapy) in patients with metastatic castration resistant prostate cancer
    • suppl; abstract 5004
    • Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab alone (or in combination with radiotherapy) in patients with metastatic castration resistant prostate cancer. J Clin Oncol 2008; 26(Suppl.):abstract 5004.
    • (2008) J Clin Oncol , vol.26
    • Beer, T.M.1    Slovin, S.F.2    Higano, C.S.3
  • 41
    • 58349090027 scopus 로고    scopus 로고
    • Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA-4 blockade and GM-CSF
    • Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA-4 blockade and GM-CSF. Cancer Res 2009; 69:609-615.
    • (2009) Cancer Res , vol.69 , pp. 609-615
    • Fong, L.1    Kwek, S.S.2    O'Brien, S.3
  • 43
    • 77954899030 scopus 로고    scopus 로고
    • Phase i study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
    • Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-3175.
    • (2010) J Clin Oncol , vol.28 , pp. 3167-3175
    • Brahmer, J.R.1    Drake, C.G.2    Wollner, I.3
  • 44
    • 79954993461 scopus 로고    scopus 로고
    • Phase Ib experience with MDX-1106, an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
    • suppl; abstract 3018
    • Brahmer JR, Topalian SL, Powderly J, et al. Phase Ib experience with MDX-1106, an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2009; 27(Suppl.):abstract 3018.
    • (2009) J Clin Oncol , vol.27
    • Brahmer, J.R.1    Topalian, S.L.2    Powderly, J.3
  • 45
    • 77749240452 scopus 로고    scopus 로고
    • XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC
    • Zhang Y, Guessous F, Kofman A, et al. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. Drugs 2010; 13:112-121.
    • (2010) Drugs , vol.13 , pp. 112-121
    • Zhang, Y.1    Guessous, F.2    Kofman, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.